Abstract
Mild cognitive impairment (MCI) is a clinical syndrome thought to represent the transition between normal function and dementia. This review describes data that support the existence of such a transitional phase, outlines the heterogeneity of MCI and how that has influenced the evolving concept of MCI, and discusses the impact of heterogeneity on recent MCI clinical trials.
Original language | English |
---|---|
Pages (from-to) | 379-388 |
Number of pages | 10 |
Journal | Annual Review of Clinical Psychology |
Volume | 2 |
DOIs | |
State | Published - 2006 |
Externally published | Yes |
Keywords
- APOE
- Alzheimer's disease
- Biomarkers
- Clinical trials
- MCI